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.Introduction: Spinal cord stimulation (SCS) may be a treatment option in limb ischemia occurring as a result of
Thromboangiitis obliterans (TAO) or secondary Raynaud’s-Syndrome (SRS). The impact of SCS on disease
progression and micro-perfusion was prospectively evaluated during a follow-up (FU) of 4 years.
Report: Under SCS, a signiﬁcant increase in trans-cutaneous oxygen tension (tcpO2) was observed in TAO and a
signiﬁcant increase in systolic perfusion pressure at plethysmography was observed in SRS. Complete limb
preservation was achieved in all patients who had reduced tobacco consumption.
Discussion: SCS is an efﬁcient therapeutic tool in TAO and SRS. Patient selection criteria are crucial for success.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd.
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Efﬁcacy of SCS has been proven in severe, otherwise
untreatable, arteriosclerotic diseases.1 Limb ischemia in
Thromboangiitis obliterans (TAO) and severe secondary
Raynaud’s-Syndrome (SRS) also may be accessible to SCS. A
4-year follow-up (FU) of nine TAO and three SRS patients
under SCS may help to evaluate treatment efﬁciency in
selected patients.REPORT
Patients were admitted following previous treatment fail-
ure. In addition to conventional vasodilatory medication,
four patients had previous Iloprost infusions and three,
sympathectomies. Connective tissue diseases in SRS (two
patients with progressive systemic scleroderma (PSS) and
one with mixed collagenosis) were treated using immu-
nosuppressive medication. Arteriosclerotic disease, hered-
itary or acquired coagulopathies were exclusion criteria.
TAO patients (all lower limb ischemia) were smokers and
diagnosis was based on the criteria of Olin. Chronic
ischemia with a trans-cutaneous oxygen pressure tension
(tcpO2) below 30 mmHg and a reserve microcirculatory
blood ﬂow (increase of tcpO2 of at least 15 mmHg,
measured on the diseased forefoot in the supine/sitting
positions) were selection criteria for TAO patients suitable
for SCS. From 2002 to 2008, SCS was started in nine TAO
patients (11 extremities) and in three SRS patients (ﬁve
upper extremities).of original article: http://dx.doi.org/10.1016/j.ejvs.2013.04.018.
responding author. L. Niclauss, Department of Cardiovascular Surgery,
Rue de Bugnon 46, CH-1011 Lausanne, Switzerland.
il address: Lars.Niclauss@chuv.ch (L. Niclauss).
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tation of the stimulation system. After epidural puncture
and quadripolar lead positioning (dorso-lumbar or cervical
spine), the pulse generator was implanted subcutaneously
(hypo-gastric region). Regular FU for 4 years included
physical examinations. tcpO2 was measured on the forefoot
for 20 minutes in the supine and sitting positions in TAO,
and systolic digital pressure by ﬁnger plethysmography in
SRS. Amputation or skin necrosis of ﬁngers or toes during
FU was considered a treatment failure.
Implantation of the system was successful, and subjective
pain reduction could be achieved in all patients with a
complete 1-year FU. Amputation of two toes at 44 months
FU (two extremities) and a toe necrosis at 6 months FU
occurred in two patients, persistent heavy smokers. The
latter was lost to FU after 1 year (94% 4-year FU). No
further amputations or ischemic lesions were observed
(Table 1).
In TAO, tcpO2 increased at 3 months staying stable for up
to 4 years (tcpO2 increase: 27  5 mmHg, 21  6 mmHg;
psupine ¼ .002, psitting ¼ .005), and claudication and rest pain
almost disappeared under SCS in cases of reduced (less than
three cigarettes per day) tobacco consumption (Table 2,
Fig. 1).
In SRS, mean systolic ﬁnger perfusion increased and also
remained stable at 4 years (mean increase of 25  6 mmHg;
p ¼ .0001), but no ischemic attacks during control exami-
nations have been provoked (Table 2, Fig. 2). An improved
quality of life, less vasospasm during the cold season (from
several attacks a day to one or two a month) and pain
reduction were reported by all SRS patients.
DISCUSSION
Patients suffering from systemic peripheral vascular dis-
eases such as TAO and SRS represent a potential target
group for SCS. Depression of sympathetic activity and
Table 1. Clinic FU e amputation rate, walking distance.
TAO e lower extremity (n ¼ 10)a TAO e lower extremity (n ¼ 8, non-smokers)
Before SCS Under SCS (FU 3 ya) p-Value Before SCS Under SCS (FU 4 y) p-Value
Fontaine classiﬁcation
I 6 (60%) .01 6 (75%) .01
II a 2 (20%) n.s. 2 (25%) n.s.
II b
III 2 (20%) n.s. 2 (25%) n.s.
IV 8 (80%) 2 (20%) .001 6 (75%) .001
Amputation rate 4 (36%) 2 (20%) n.s. 4 (36%) None .05
Note. FU ¼ follow-up; n.s. ¼ not signiﬁcant; SCS ¼ spinal cord stimulation; TAO ¼ Thromboangiitis obliterans; y ¼ years.
a One patient lost to FU.
Table 2. tcpO2 and plethysmography results before and under SCS.
Before
SCS
Under SCS
(FU 3
months)
Difference
of mean
95% CI of
difference
p-Value Under
SCS
(FU 4 y)
Difference
of mean
95% CI of
difference
p-Value
TAO e lower extremity (n [ 11)a
tcpO2 mean  SD
Supine (mmHg) 16  11 40  7 24  4 16e32 .0001 38  19 23  7 9e37 .003
Sitting (mmHg) 38  15 61  8 23  5 12e34 .0003 53  20 16  8 1e32 .07
TAO e lower extremity (n [ 8, non-smokers)
tcpO2 mean  SD
Supine (mmHg) 19  11 40  6 21  5 12e32 .0005 47  8 27  5 16e38 .002
Sitting (mmHg) 42  15 60  8 18  6 5e31 .01 63  5 21  6 8e34 .005
Secondary Raynaud’s-Syndrome (n [ 5)
Plethysmography mean  SD (mmHg) 93  15 120  12 28  4 19e36 .0001 118  21 25  6 13e37 .0001
Note. FU ¼ follow-up; SCS ¼ spinal cord stimulation; TAO ¼ Thromboangiitis obliterans; tcpO2 ¼ trans-cutaneous oxygen pressure
tension; y ¼ years.
a One patient/one extremity lost to 4-y FU.
e10 EJVES Extra Volume 26 Issue 1 July/2013subsequently reduced vasoconstriction and antidromic
activation of sensory ﬁbers leading to the release of vaso-
dilators may be the mechanisms responsible for increased
blood ﬂow.2
Compared with arteriosclerosis, TAO affects small and
medium sized arteries and the vascular wall is preserved (no
internal elastic lamina and media disruption). A reactive
wall, being the site of action for vaso-active mediators, may
explain the efﬁciency of SCS.3Figure 1. Mean tcpO2 during FU under SCS in TAO of the lower extremi
TAO ¼ Thromboangiitis obliterans; tcpO2 ¼ trans-cutaneous oxygen pContrary to idiopathic Raynaud’s disease, endothelial
damage is frequent in SRS.4 SCS may counteract systemic
inﬂammatory response and consecutive vasospasms similar
to arteriosclerosis.
Under SCS amputation rate decreased in cases of reduced
tobacco abuse, and no further ischemic lesions were
observed during FU. Objective parameters, namely tcpO2
and plethysmography values, increased and indicated a
better micro-perfusion.ties. FU ¼ follow-up; mo ¼ months; SCS ¼ spinal cord stimulation;
ressure tension; y ¼ years. *At 4-y follow-up.
Figure 2. Finger plethysmography under SCS in secondary Raynaud’s-Syndrome. FU ¼ follow-up; mo ¼ months; SCS ¼ spinal cord
stimulation; y ¼ years; SD ¼ standard deviation.
L. Niclauss et al. e11Good 4-year outcome in TAO is certainly a result of
rigorous selection criteria. A sufﬁcient preoperative tcpO2
gradient seems to be a reliable and repeatable parameter,
indicating potential reserve blood ﬂow recruitment via
reactive micro-perfusion. Under SCS the initial increase of
supine tcpO2 reaches the level of preoperative sitting tcpO2
values, similar to previous observations in arteriosclerosis
(Fig. 1). A better micro-perfusion seems to be measurable
and durable in TAO, but SCS cannot counteract the negative
effects of persistent heavy smoking. Rapid symptom relief
was accompanied by an early increase of tcpO2. Promising
results have been reported; however, concrete inclusion
criteria for TAO patients accessible to this therapy are
missing.3
In SRS quality of life was improved and plethysmography
conﬁrmed a normal systolic ﬁnger perfusion under SCS, but
this was outside of ischemic attacks. One problem assessing
efﬁcacy is the lack of objective parameters. Iterative mea-
surements of vascularization outside acute ischemia are
certainly of limited informational value. Association of SRS
with PSS is characterized by an alteration of vessel wall
structures, and, although previous studies show good clin-
ical results, under SCS no increase of perfusion pressures
was observed at plethysmography, contrary to our experi-
ence.5 Normal systolic ﬁnger perfusion may indicate a sta-
ble clinical evolution without signs of disease progression in
the extremities.
SCS in TAO and SRS show good results in terms of quality
of life, pain reduction and wound healing in cases of
reduced smoking. Sufﬁcient microcirculatory blood ﬂow
reserve, measured by preoperative tcpO2 gradients, seemsto be reliable selection criterion for successful outcome in
TAO. General conclusions are limited because of the small
collectives of patients with rare diseases, the lack of control
groups and quality of life assessment scores.
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